3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
7
Unknown
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
53
Biliary Tract Neoplasms
23
Nasopharyngeal Carcinoma
22
Carcinoma, Non-Small-Cell Lung
22
Cholangiocarcinoma
21
Urinary Bladder Neoplasms
18
Breast Neoplasms
18
Neoplasm Metastasis
17
Lung Neoplasms
14
Lymphoma, Large B-Cell, Diffuse
13
Colorectal Neoplasms
12
Carcinoma, Transitional Cell
12
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
8
Ovarian Neoplasms
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Neoplasms
6
Hodgkin Disease
6
Gallbladder Neoplasms
6
Nasopharyngeal Neoplasms
5
Bile Duct Neoplasms
5
Adenocarcinoma
5
Uterine Cervical Neoplasms
4
Locally Advanced Pancreatic Cancer
4
Endometrial Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Adenocarcinoma
3
Osteosarcoma
3
Lymphoma
3
Interventions
Carboplatin
4
pembrolizumab
3
Nivolumab
3
fludarabine
2
atezolizumab
2
Pemetrexed
2
Ipilimumab
2
Cyclophosphamide
2
tremelimumab
1
sotorasib
1
osimertinib
1
olaparib
1
durvalumab
1
Tumor Burden
1
Thoracoscopy
1
Tablets
1
Saline Solution
1
Quality of Life
1
Observation
1
Magnesium Sulfate
1
Injections
1
Influenza Vaccines
1
Histocompatibility Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Exercise Therapy
1
Combined Modality Therapy
1
Cisplatin
1
Cell- and Tissue-Based Therapy
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Mesothelioma
×
Gemcitabine
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled